+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
226.8300
-.2648
-.2756
4.6764
.5551
.3304
Low
72.0825
4.8398
Yes
No
No
No
No
No
0.6
Yes
No
No
No
Aloinoside B (CAS No.: 11006-91-0) is an important natural anthraquinone compound, mainly isolated from plants of the genus Aloe. As a hot topic in pharmacological research of natural products, aloe glycoside B has attracted widespread attention due to its unique chemical structure and diverse bioactivity, especially its potential applications in skin repair. In recent years, with in-depth research on aloe glycoside B, the biological functions of its metabolites such as aloin, isoaloside, and hydroxyl metabolites have gradually been revealed, further enriching the pharmacological understanding of this class of anthraquinone derivatives.
This review aims to systematically summarize the chemical structure and physicochemical properties of aloe glycoside B, plant origin and extraction methods, pharmacological activity, and mechanism of action. It focuses on its molecular targets and pathways in skin repair, and, combined with druggability evaluation and pharmacokinetic data, anticipates its clinical application potential and future research directions, providing theoretical basis and research ideas for natural product pharmacology and new drug development.
Aloe glycoside B belongs to the anthraquinone class of compounds with a complex molecular formula and a molecular weight of 564.5400, indicating it is a relatively large glycoside anthraquinone derivative. Its structure contains a typical anthraquinone backbone, linked to multiple hydroxyl and glycosyl groups, which give it high polarity and water solubility. Its LogP value is -0.2648, indicating strong hydrophilicity, with a water solubility index of 4.6764, supporting its good solubility in the aqueous phase. The highly polar molecular structure also results in a topological pole surface area (TPSA) of 226.83 Ų, suggesting limited penetration of cell membranes.
The physicochemical properties of aloe glycoside B determine its absorption, distribution, and metabolic characteristics in the body. Its lower blood-brain barrier permeability indicates that the compound has difficulty entering the central nervous system, reducing the risk of CN toxicity. Additionally, the hERG channel inhibition test results were negative, indicating a low risk of cardiotoxicity. The Ames trial scored 0.6, indicating a low genotoxicity risk and meeting the preliminary safety evaluation requirements.
Aloe glycoside B is mainly found in plants of the Aloe genus (Aloe spp.), especially in the sap and epidermal tissue of aloe vera leaves, where the content is relatively high. Aloe plants are widely distributed in tropical and subtropical regions and have been extensively studied for their abundant bioactive components and traditional medicinal value.
Traditional methods for extracting aloe glycoside B mainly include solvent extraction and chromatographic separation. Generally, ethanol or methanol is used as extraction solvents, and extraction efficiency is improved through ultrasound-assisted extraction or reflux extraction. Subsequently, the crude extract was separated and purified using liquid-liquid partitioning, silica gel column chromatography, and high-performance liquid chromatography (HPLC) techniques, ultimately obtaining high-purity aloe glycoside B. In recent years, the application of supercritical CO₂ extraction and membrane separation technology has further optimized extraction processes, improving yield and purity, and making them more environmentally friendly and efficient.
Additionally, research shows that the content of aloe glycoside B in plants is significantly affected by growth environment, harvest time, and treatment methods, posing challenges to standardizing extraction processes and industrializing production. In the future, it is necessary to further establish standardized planting and harvesting systems, combined with modern extraction technologies, to ensure a stable supply of aloe glycoside B.
Aloe glycoside B has multiple biological activities, especially showing significant pharmacological effects in the field of skin repair. Its main pharmacological effects include promoting cell proliferation and migration, regulating extracellular matrix remodeling, anti-inflammation, and promoting angiogenesis.
Aloe glycoside B promotes skin damage repair by regulating various key enzymes and growth factors. In vitro and in vivo experiments have shown that this compound can significantly downregulate the expression of matrix metalloproteinases (MMP1, MMP2, MMP9), inhibit excessive collagen degradation, and maintain the structural integrity of skin tissue. At the same time, aloe glycoside B activates epidermal growth factor receptor (EGFR) and fibroblast growth factor 2 (FGF2), promoting the proliferation and migration of keratinocytes and fibroblasts, accelerating wound healing.
Additionally, aloe glycoside B upregulates the expression of transforming growth factor β1 (TGFB1) and collagen type III (COL3A1) and type IV (COL4A1), promoting the synthesis and remodeling of the extracellular matrix, enhancing the skin's mechanical strength and elasticity. The induced expression of vascular endothelial growth factor A (VEGFA) promotes angiogenesis, improves local blood supply, and further supports tissue repair.
Aloe glycoside B and its metabolites exhibit good anti-inflammatory activity, inhibiting the release of inflammatory mediators, reducing inflammatory responses, and preventing chronic inflammation from damaging the skin. Its antioxidant capacity works by scavenging free radicals, reducing oxidative stress damage to cells, and protecting the integrity of cell membranes and DNA.
Rat gut bacteria can metabolize aloe glycoside B into aloin glucosides, isoalosides, and hydroxy metabolites, which may exert synergistic or different pharmacological effects in the body. For example, aloe glycoside and isoaloside have been shown to have anti-inflammatory and cell regeneration functions, suggesting that the in vivo activity of aloe glycoside B may partly depend on its metabolic transformation.
The mechanism of aloe glycoside B in skin repair involves multiple signaling pathways and regulation of key molecular targets, mainly including the following aspects:
MMP1, MMP2, and MMP9 are key proteases involved in collagen degradation and extracellular matrix remodeling. Aloe glycoside B inhibits the overexpression of these MMPs, prevents excessive collagen degradation, maintains skin structure stability, and promotes wound healing.
EGFR and FGF2 are important signaling molecules regulating cell proliferation and migration. Aloe glycoside B can activate the EGFR signaling pathway, promote the proliferation and migration of keratinocytes, and simultaneously stimulate FGF2 expression, enhancing fibroblast activity and synergistically promoting skin tissue repair and regeneration.
TGFB1, as a key regulator of extracellular matrix synthesis, plays a central role in fibrosis and tissue repair. Aloe glycoside B upregulates TGFB1 expression, promotes collagen synthesis (COL3A1, COL4A1), enhances the skin's mechanical strength and elasticity, and aids tissue remodeling.
VEGFA is a key factor in angiogenesis. Aloe glycoside B promotes angiogenesis by inducing VEGFA expression, improving local blood circulation, enhancing nutrient supply and metabolic waste removal, and supporting the skin repair process.
ITGB1 acts as a linking molecule between cells and the matrix, regulating cell adhesion, migration, and signal transduction. Aloe glycoside B regulates ITGB1 expression, promotes cell-matrix interaction, enhances cell migration ability, and facilitates wound closure.
The druggability evaluation of aloe glycoside B shows it has a solid foundation for safety and pharmacological activity. Its relatively large molecular weight (564.54 Da) and high TPSA value (226.83 Ų) suggest that its oral bioavailability may be limited and requires optimization of drug formulations or adjustments of administration routes to improve in vivo absorption.
The LogP value was -0.2648, indicating strong hydrophilicity, which is beneficial for the development of water-soluble formulations but may affect cell membrane penetration ability. The blood-brain barrier has lower permeability, reducing the risk of central nervous system toxicity. hERG inhibition test was negative, reducing the risk of cardiotoxicity. Ames test results showed that it carries a low genotoxicity risk and meets safety requirements.
Pharmacokinetics, aloe glycoside B is mainly metabolized in the gut microbiota into aloin glycosides, isoalosides, and hydroxyl metabolites, suggesting that its activity in vivo may partially depend on metabolites. The pharmacological activity and metabolic kinetics of metabolites require further systematic research to clarify their in vivo mode of action and safety.
As a natural anthraquinone compound, aloe glycoside B shows broad application prospects in skin repair and related disease treatment. Its multi-target regulatory mechanism and solid safety foundation make it an ideal candidate for the development of novel skin repair agents, wound dressings, and anti-inflammatory drugs.
Future research should focus on the following directions:
Drug formulation optimization: Develop suitable delivery routes based on the physicochemical properties of aloe glycoside B, such as topical formulations and nanocarrier systems, to improve bioavailability and targeting.
Metabolite activity research: In-depth analysis of the pharmacological effects of aloe glycoside B metabolites and their synergistic effects with parent compounds to clarify their in vivo action networks.
Mechanisms and signaling pathways: Combining modern molecular biology techniques, further elucidating the molecular mechanisms by which aloe glycoside B regulates skin repair-related signaling pathways, and uncovering potential new targets.
Preclinical and clinical research: Conduct systematic pharmacodynamics, safety evaluations, and clinical trials to verify the efficacy and safety of skin injuries, chronic wounds, and inflammatory skin diseases.
Standardized production and quality control: Establish a standardized extraction, purification, and quality control system for aloe glycoside B to ensure the stability and consistency of its medicinal components.
Aloe glycoside B, as a natural anthraquinone compound with significant biological activity, demonstrates unique pharmacological advantages in the field of skin repair. It regulates skin cell proliferation, migration, inflammatory responses, and angiogenesis through multiple targets and pathways, promoting tissue repair and regeneration. Combined with its excellent safety and druggability, aloe glycoside B has broad clinical application potential.
In the future, by deepening research into its mechanism of action, optimizing drug formulations, and conducting clinical validation, it is expected that aloe glycoside B and its derivatives will become a new generation of natural skin repair drugs, providing innovative solutions for skin injury treatment and promoting the integration of natural product pharmacology with modern medicine.
Shenshuai
Wenjing
Hedandan
